ALGAE TEC LTD/S (ALGXY) vs. Cleveland BioLabs (CBLI) Financial Review

ALGAE TEC LTD/S (OTCMKTS:ALGXY) and Cleveland BioLabs (NASDAQ:CBLI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations and valuation.

Insider and Institutional Ownership

0.1% of ALGAE TEC LTD/S shares are owned by institutional investors. Comparatively, 4.6% of Cleveland BioLabs shares are owned by institutional investors. 2.0% of Cleveland BioLabs shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares ALGAE TEC LTD/S and Cleveland BioLabs’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ALGAE TEC LTD/S $2.05 million 1.48 -$6.08 million N/A N/A
Cleveland BioLabs $1.95 million 10.14 -$9.70 million N/A N/A

ALGAE TEC LTD/S has higher revenue and earnings than Cleveland BioLabs.

Volatility and Risk

ALGAE TEC LTD/S has a beta of 92.6, meaning that its stock price is 9,160% more volatile than the S&P 500. Comparatively, Cleveland BioLabs has a beta of -0.34, meaning that its stock price is 134% less volatile than the S&P 500.


This table compares ALGAE TEC LTD/S and Cleveland BioLabs’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cleveland BioLabs -252.15% -65.66% -50.21%

Analyst Ratings

This is a summary of recent ratings for ALGAE TEC LTD/S and Cleveland BioLabs, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cleveland BioLabs 0 0 0 0 N/A


ALGAE TEC LTD/S beats Cleveland BioLabs on 6 of the 9 factors compared between the two stocks.

ALGAE TEC LTD/S Company Profile

Affinity Energy and Health Limited produces and sells algal oil and biomass primarily to the nutraceutical market in Australia, India, and the United States. It offers algae products, such as proteins for consumption; and biofuel oils for the transportation and power generation. The company was founded in 2007 and is based in Perth, Australia.

Cleveland BioLabs Company Profile

Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in radiation mitigation, oncology immunotherapy, and vaccines. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and an immunotherapy for oncology and other indications. Its development programs include CBLB612, which is in preclinical studies, a synthetic molecule that activates the toll-like heterodimeric receptor 2/6 and stimulated white blood cell generation; and that has completed Phase II for treating myelosuppressive prophylaxis in patients with breast cancer receiving doxorubicin-cyclophosphamide chemotherapy. The company is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic and Roswell Park Cancer Institute. The company was founded in 2003 and is headquartered in Buffalo, New York.

Receive News & Ratings for ALGAE TEC LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALGAE TEC LTD/S and related companies with's FREE daily email newsletter.

Leave a Reply